𝛼SK or Search

ENTITY

Ekf Diagnostics Holdings (EKF LN)

5

Analysis

Health Care • United Kingdom

EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Africa, Asia, and internationally. It offers hemoglobin analyzers, including DiaSpect Tm, a hand-held hemoglobin analyzer; DiaSpect Hemoglobin T Low to determine low levels of hemoglobin in plasma and serum specimens, aqueous solutions, or stored or banked erythrocytes; Hemo Control, a hemoglobin analyzer that provides quantitative laboratory quality results for blood banks, hospitals, and doctors? offices; HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples; STAT-Site M Hgb, a battery operated portable hemoglobin analyzer; and UltraCrit Plus, a hematocrit analyzer that delivers measurements for blood donor screening and sports medicine. The company also provides glucose analyzers, such as C-Line GP+, C-Line Clinic, and S-Line Lab+ used in laboratories, diabetes institutions, and sports institutions; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes in a point-of-care setting; and STAT-Site M �-HB analyzer for the quantitative determination of beta-hydroxybutyrate in serum or plasma. In addition, it offers Creamatocrit Plus, a system to measure creamatocrit; and pregnancy tests, such as True20 and QuPID for urine only or urine and serum pregnancy testing. Further, the company offers Sepsis testing services; and clinical chemistry reagents. It sells its products directly to GP surgeries, sports and diabetes clinics, blood banks, hospitals, laboratories, and government agencies, as well as through a network of distributors. Additionally, the company services and distributes third party company products under separate distribution agreements. EKF Diagnostics Holdings plc was founded in 1990 and is headquartered in Cardiff, the United Kingdom.

more

Refresh

Focused

bullish•Ekf Diagnostics Holdings

•15 Oct 2025 14:28•Primer

Primer: Ekf Diagnostics Holdings (EKF LN) - Oct 2025

EKF Diagnostics is pivoting its business model towards higher-margin products within its core Point-of-Care and Life Sciences segments,...

αSK

216 Views

Share

bullish•Thematic (Sector/Industry)

•10 Jan 2025 22:18•Issuer-paid

Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences

The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments...

Hardman & Co

475 Views

Share

bullish•TMT Investments

•31 Mar 2026 22:03•Issuer-paid

TMT Investments PLC - Hybridan Small Cap Feast: 24 March 2026

The highest grade recorded at the Monte Muambe project was recorded with Hole MM156 returning 30 metres at 42.5% CaF₂ from surface.

Hybridan

113 Views

Share

bullish•Xeros Technology

•03 Feb 2026 20:00•Issuer-paid

Xeros Technology Group plc - Hybridan Small Cap Feast: 27 January 2026

The Company expects to make rapid progress now that construction is underway and anticipates this is the first of six apartment blocks of the same...

Hybridan

118 Views

Share

bullish•Oxford Nanopore Technologies

•11 Jan 2025 02:00•Issuer-paid

Hardman & Co Monthly: January 2025

Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to...

Hardman & Co

630 Views

Share

No more insights

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.69.1

x